Navigation Links
Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
Date:11/7/2011

h the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document. Clinical and corporate milestones guidance is as of November 7, 2011 and financial guidance relating to the Company's current cash, cash equivalents and investments is based upon balances as of September 30, 2011.

This news release and the conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, i
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
3. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
4. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
5. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
6. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
8. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
9. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
10. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
11. Alexza to Present at the MDB Bright Lights Conference 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... (HealthDay News) -- When it comes to firearm deaths, ... States, while the District of Columbia has the highest, ... deaths from gun-related violence -- including murders, suicides and ... the study revealed. Hawaii,s rate was roughly three per ... the District of Columbia had the highest rate of ...
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows ... and Bluehost are the best suppliers of 2014. ... hosting (including VPS and cloud hosting) at affordable ... information. , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business ... fraction of the cost. As a top rated ...
(Date:9/19/2014)... patients with advanced, incurable cancer do not receive any ... this month at the ESMO 2014 Congress in Madrid, ... come at the same time as 15 new oncology ... being awarded the prestigious title of ,ESMO Designated Centre ... Dr Alexandru Grigorescu, medical oncology consultant at the Institute ...
(Date:9/19/2014)... 2014 Follow us on ... for detection and quantification of the presence of ... by steady expansion in immunodiagnostics and technological advancements ... systems market has evolved remarkably well over the ... diabetes, cardio-vascular ailments, infectious diseases, allergy and cancer, ...
Breaking Medicine News(10 mins):Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4
... By Amanda Gardner HealthDay Reporter , ... that derives fats and proteins from vegetable sources rather ... Comparing the two types of diets over two decades, ... reduced rates of death from cardiovascular disease and cancer, ...
... States must focus on conserving the use of antibacterial ... rising rates of antibiotic-resistant infections, according to an analysis ... of antibiotics is being depleted by resistance, which occurs ... no longer respond to widely-used treatments. Most proposals to ...
... The Endocrine Society released a new clinical practice guideline ... (CAH). The guideline features a series of evidence-based clinical ... guideline, published in the September 2010 issue of the ... JCEM ), a publication of The Endocrine Society, is ...
... methods, researchers at the University of California, San Diego ... spend significantly more time visually examining dynamic geometric patterns ... viewing pattern not found in either typical or developmentally ... that a preference for geometric patterns early in life ...
... psychotic disorders and living in urban areas appears to ... cities, according to a report in the September issue ... the JAMA/Archives journals. "There is a ... authors write as background in the article. "The clearest ...
... blood levels of chemicals used in the production of ... have elevated total and LDL cholesterol levels, according to ... of Pediatrics & Adolescent Medicine , one of the ... compounds known as perfluoroalkyl acidsincluding perfluorooctanoic acid (PFOA) and ...
Cached Medicine News:Health News:Low-Carb Diets Heavy on Meat May Raise Health Risks 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Experts recommend universal screening of newborns for congenital adrenal hyperplasia 2Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3Health News:Study examines association between urban living and psychotic disorders 2Health News:Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens 2
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Ruler S/Steel....
Medicine Products: